Korean J Hematol 2006; 41(3):
Published online September 30, 2006
https://doi.org/10.5045/kjh.2006.41.3.215
© The Korean Society of Hematology
오소연, 장문주, 장세경, 오도연, 정소영
포천중문의과대학교, 내과학교실, 방사선종양학과
Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
Keywords Mantle cell lymphoma, Hyper-CVAD, Rituximab, Autologous stem cell transplantation
Korean J Hematol 2006; 41(3): 215-219
Published online September 30, 2006 https://doi.org/10.5045/kjh.2006.41.3.215
Copyright © The Korean Society of Hematology.
오소연, 장문주, 장세경, 오도연, 정소영
포천중문의과대학교, 내과학교실, 방사선종양학과
So Yeon Oh, Moon Ju Jang, Sei Kyung Chang, Do yeon Oh, So Young Chong
Departments of, Internal Medicine, Radiation Oncology, Pochon CHA University College of Medicine, Seongnam, Korea
Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
Keywords: Mantle cell lymphoma, Hyper-CVAD, Rituximab, Autologous stem cell transplantation
Yoon Seok Choi
Blood Res 2020; 55(S1): S58-S62Byung Woog Kang, Sang Kyun Sohn, Joon Ho Moon, Yee Soo Chae, Jong Gwang Kim, Soo Jung Lee, Won Seog Kim, Je-Jung Lee, Se Ryeon Lee, Keon Uk Park, Ho Sup Lee, Won Sik Lee, Jong-Ho Won, Moo-Rim Park, Jae-Yong Kwak, Min Kyoung Kim, Hyo Jung Kim, Sung Yong Oh, Hye Jin Kang, and Cheolwon Suh
Blood Res 2014; 49(1): 15-21Sung Hwa Bae, Sung-Hyun Kim, Soo-Mee Bang
Blood Res 2022; 57(S1): S37-S43